Merkel cell carcinoma (MCC) is a complex, rare, aggressive disease that requires the expertise of multiple disciplines. As highlighted in the review by Banks et al, 1 we have seen some recent ...

Dr. Ko Un “Clara” Park and Dr. Mylin Torres present the latest evidence-based changes to the SLNB in early-stage breast cancer guideline. They discuss the practice-changing trials that led to the ...

Lymph node status in stage I hormone receptor-positive/HER2-negative breast cancer was not a good indicator of genetic-risk scores that would qualify older women for ...

Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...

Please provide your email address to receive an email when new articles are posted on . Skipping sentinel lymph node biopsy can be considered for node-negative, HR-positive, HER2-negative early breast ...

Omitting SLNB in older patients with early-stage, HR-positive, HER2-negative breast cancer showed similar safety and efficacy to performing the procedure. The BOOG 13-08 trial demonstrated comparable ...

Limited data are available on survival outcomes after sentinel-lymph-node biopsy alone as compared with lymphadenectomy in cervical cancer. In this multicenter, randomized, noninferiority trial, we ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...

Sentinel lymph node (SLN) biopsy for early cervical cancer achieved non-inferiority versus pelvic lymphadenectomy, according to results of a large randomized study from China. Patients assigned to SLN ...